Key facts
- This page summarizes Garry E. Menzel's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2023, 16:59.
Garry E. Menzel - 01 Jun 2023 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)
- Reporting relationship
- Director
- Issuer ticker
- ADAP
- Reported as of
- 01 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2023, 16:59:07 UTC
- Prior SEC filing
- 17 May 2023
- Next SEC filing
- 15 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Garry E Menzel**
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Garry E. Menzel filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 01 Jun 2023.
Change
- Previous filing in this sequence was filed on 17 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADAP
transaction
American Depositary Shares representing Ordinary Shares
Award
- Transaction value
- Shares
- +200,646
- Change %
- Price
- Shares after
- 200,646
- Date
- 01 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3, F4
ADAP
transaction
American Depositary Shares representing Ordinary Shares
Award
- Transaction value
- Shares
- +200,647
- Change %
- Price
- Shares after
- 200,647
- Date
- 01 Jun 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3, F5, F6
ADAP
transaction
American Depositary Shares representing Ordinary Shares
Award
- Transaction value
- Shares
- +209,931
- Change %
- Price
- Shares after
- 209,931
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Garry E. Menzel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 7 footnotes
Footnote F1
Each American Depositary Share of the Issuer (each, an "ADS") represents six ordinary shares of the Issuer (each, an "Ordinary Share"), nominal value GBP 0.001 per Ordinary Share, of the Issuer.
Footnote F2
Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub will be merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. At the effective time of the Merger, each share of TCRR common stock was cancelled and converted into the right to receive 1.5117 ADSs (the "ADS Exchange Ratio"), rounded down to the nearest whole ADS. On May 31, 2023, the last trading day before the effective time of the Merger, the closing price of shares of TCRR common stock was $1.48 per share, and the closing price of the Issuer's ADSs was $1.02 per share.
Footnote F3
Received 200,646 ADSs, representing 1,203,876 Ordinary Shares in exchange for 132,729 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.
Footnote F4
ADSs held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The Reporting Person is the trustee of the Menzel Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
Footnote F5
Received 200,647 ADSs, representing 1,203,882 Ordinary Shares in exchange for 132,730 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.
Footnote F6
ADSs held by the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The Reporting Person's spouse is the trustee of the Henshall Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
Footnote F7
Received 209,931 ADSs, representing 1,259,586 Ordinary Shares of the Issuer in exchange for 138,871 shares of TCRR common stock in connection with the Merger and pursuant to the terms of the Merger Agreement.